MYD88 and neoplasm: To clarify the detailed mechanism of anti-tumor immunomodulatory effects of APS and to verify whether APS activates TLR4 signaling pathway through MyD88-dependent pathway, we used C57BL/6J (MyD88+/+) and MyD88-deficient (MyD88−/−) tumor-bearing mice in this study.